Published by Iain Gilbert on 2nd June 2025
(Sharecast News) - Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US Food and Drug Administration for use in cholestatic pruritus patients with primary biliary cholangitis.
URL: http://www.digitallook.com/dl/news/story/35119094/...